Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

GOAL.MD vs June Health

GOAL.MD
Graded #142

Higher grade

vs+5.599999999999994
June Health
Graded #261

Lower grade

The verdict

GOAL.MD takes it — 68.6/100 to 63/100.

GOAL.MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. GOAL.MD is a St. Louis-based telehealth platform offering compounded semaglutide alongside brand-name bridges to Ozempic, Wegovy, and Zepbound. Its standout is a manual-renewal model — no auto-billing

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGOAL.MD +4
65
61
Dose & formulationGOAL.MD +11
86
75
Clinical oversightGOAL.MD +9
68
59
Labs & monitoringGOAL.MD +2
53
51
FulfillmentGOAL.MD +3
77
74
Contract termsEven
55
55
GOAL.MD · left barJune Health · right bar

The numbers

MetricGOAL.MDJune Health
WeighScore68.6/10063/100
GradeCC
Scorecard rank#142#261
Semaglutide$179/mo$179/mo (starting dose, compounded)
Tirzepatide$249/mo (starting dose, compounded)$179/mo (starting dose, compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualYesYes
GOAL.MD

Graded #142 · C

Strengths

  • Transparent dose-tiered pricing on brand pens
  • LegitScript Certified
  • Manual-renewal model — no surprise auto-billing
  • Free nutrition coach included
  • BBB A+ rating since 2021

Where it loses points

  • No named compounding pharmacy partner
  • Co-founder and chief physician has a 2016 federal guilty plea for distributing misbranded HGH and a (reinstated) license revocation
  • No URAC or PCAB pharmacy accreditation
June Health

Graded #261 · C

Strengths

  • Offers both injectable and oral compounded semaglutide and tirzepatide
  • Semaglutide starts at $179/mo (injectable) or $187/mo (tablets) — tirzepatide from $179/mo (injectable)
  • Full per-dose price list published on-site with no signup required to view it
  • Provider consult ('licensed clinician evaluation') is bundled into the displayed price
  • Free discreet shipping advertised with 2-3 day delivery

Where it loses points

  • No accessible Terms of Service or Privacy Policy — footer links go nowhere and standard URL guesses 404
  • No LegitScript seal or other pharmacy-verification badge found anywhere on the site
  • Legal entity, prescribing medical group, and compounding pharmacy partner are not named
  • Domain was registered in May 2026 — a brand-new storefront with no independent reviews found
  • Also sells 'MR-3' (retatrutide), a GLP-1/GIP/glucagon agonist with no FDA approval for any use

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard